Sign In
Buy HQL
$18.63
+0.290 (+1.58%)
At Close: Jun 23, 2026
PHILADELPHIA, PA / ACCESSWIRE / October 27, 2023 / Effective close of business today, October 27, 2023, abrdn Inc. ("abrdn") assumed responsibility for the management of the four (4) former Tekla Capi
Tekla Capital Management LLC Announces Closing of Transaction With abrdn
04:57pm, Friday, 27'th Oct 2023
Tekla Capital Management LLC (Tekla) announced today that it has completed the sale of its advisory business to abrdn Inc. In addition, effective close of regular business, abrdn was approved as manag
Tekla Funds Approve New Investment Advisory Agreements With abrdn Inc.
04:57pm, Friday, 27'th Oct 2023
BOSTON--(BUSINESS WIRE)--Tekla Capital Management LLC (Tekla) announced today that the requisite vote has been attained to approve the new investment advisory agreement with abrdn Inc. for each of its
Tekla Life Sciences Investors Paid Distribution
10:35am, Friday, 29'th Sep 2023
BOSTON--(BUSINESS WIRE)--On September 29, 2023, Tekla Life Sciences Investors paid a distribution of $0.32 per share. It is currently estimated that this distribution is derived from net realized long
HQL: Hold Your Investments In This Healthcare CEF For Strong, Steady Yield
02:34pm, Wednesday, 27'th Sep 2023
Tekla Life Sciences Investors invests primarily in biotechnology stocks, and 10-12 large-cap biotech stocks (50% of total holdings) sets the trend and price direction for this fund. Poor price growth
Tekla Life Sciences Investors Declares Distribution
09:55am, Tuesday, 15'th Aug 2023
BOSTON--(BUSINESS WIRE)--On August 15, 2023, Tekla Life Sciences Investors declared a distribution of $0.32 per share. The record date for the distribution is August 25, 2023 and the payable date is S
Tekla Funds Announce Adjournment of Special Meetings
03:10pm, Monday, 14'th Aug 2023
BOSTON--(BUSINESS WIRE)--Tekla Healthcare Investors (HQH), Tekla Life Sciences Investors (HQL), Tekla Healthcare Opportunities Fund (THQ) and Tekla World Healthcare Fund (THW), (the “Funds”) today
HQL: 13% Discount Creates An Opportunity
08:06am, Thursday, 29'th Jun 2023
Tekla Life Sciences Investors is a closed-ended equity fund that primarily invests in the life sciences sector, with a heavy focus on biotech and pharmaceuticals.
HQL: Boom-Bust Returns May Not Be Suitable For High Distribution Yield
03:27am, Wednesday, 08'th Mar 2023
HQL focuses on the life sciences industry with a 74% allocation to biotechnology stocks. It pays a 2% quarterly managed distribution.
Equity CEFs: Top Picks For 2023
12:29pm, Monday, 09'th Jan 2023
2022 was a year to forget, while most believe 2023 will begin with the same issues that took the equity and bond markets well into bear market territory last year. That is, a hawkish Federal Reserve t
5 Best CEFs To Buy This Month (December 2022)
09:30am, Wednesday, 14'th Dec 2022
For income investors, closed-end funds remain an attractive investment class that covers a variety of asset classes and promises high distributions and reasonable total returns. Closed-end funds are g
Equity CEFs: What's Going On With Tekla's HQH And HQL?
10:36am, Thursday, 08'th Dec 2022
The iShares Biotechnology ETF (IBB) is down -12.9% year-to-date but the Tekla biotech equity CEFs are down even more despite NAVs that are holding up extremely well. The result is that the Tekla biote
Tekla Life Sciences Investors: 10% Yield And Trading 10.5% Below NAV
08:39am, Sunday, 23'rd Oct 2022
Tekla Life Sciences currently has a high 10% yield. The CEF is currently trading 10.5% below NAV, providing a better entry point.
HQL: A Biotechnology Equity CEF With No Leverage
04:47pm, Tuesday, 12'th Jul 2022
Tekla Life Sciences Investors is a closed-end fund focused on biotechnology and pharmaceutical stocks. The fund does not employ leverage and has an annualized 5-year total return of only 2.3% while it
HQL: Buy For The Yield, If You Can Stomach The Depreciation
02:38pm, Wednesday, 27'th Apr 2022
HQL pays regular quarterly dividends with a close to double-digit yield, and despite poor price growth over medium and long run, HQL's total return is impressive. In the past three months, a dividend
